FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab

(MedPage Today) -- Treatment options for relapsed/refractory multiple myeloma continue to expand with FDA's accelerated approval of teclistamab (Tecvayli).
The approval stipulates use of the bispecific antibody in adults who have received at least...